NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary
Adicet Bio Q2 net loss narrows
Brief: Adicet Bio Q2 Basic EPS USD -1.99
Adicet Bio Inc expected to post a loss of $2.03 a share - Earnings Preview
Adicet Bio Q1 net loss narrows on lower expenses
Brief: Adicet Bio Q1 Basic EPS USD -1.88
Adicet Bio Q4 net loss widens
Brief: Adicet Bio Q4 Basic EPS USD -2.94
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
U.S. STOCKS ON THE MOVE-Target, natgas firms, copper miners
U.S. STOCKS ON THE MOVE-Target, natgas firms, copper miners
Adicet Bio slides after announcing one-for-16 reverse stock split
Brief: Adicet Bio Announces Reverse Stock Split
U.S. STOCKS ON THE MOVE-Adicet Bio, Coupang, Biohaven,
Adicet Bio slides after announcing one-for-16 stock split